Kymera Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
27 févr. 2025 07h00 HE
|
Kymera Therapeutics, Inc.
KT-621 (STAT6) Phase 1 healthy volunteer trial ongoing, complete SAD/MAD data expected in June 2025 KT-621 Phase 1b trial in atopic dermatitis (AD) patients expected to initiate in 2Q25 with data in...
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
26 févr. 2025 07h00 HE
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader...
Kymera Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 27
20 févr. 2025 07h00 HE
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader...
Kymera Therapeutics to Participate in Upcoming February Investor Conferences
30 janv. 2025 07h00 HE
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader...
Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs
14 janv. 2025 07h00 HE
|
Kymera Therapeutics, Inc.
KT-621 (STAT6) Phase 1 healthy volunteer trial ongoing, with data expected in 2Q25 Kymera plans to initiate a KT-621 Phase 1b trial in atopic dermatitis (AD) patients in 2Q25 with data in 4Q25 and...
Kymera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14
07 janv. 2025 07h00 HE
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader...
Kymera Therapeutics to Participate in Upcoming December Investor Conferences
26 nov. 2024 07h00 HE
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using...
Kymera Therapeutics to Participate in Upcoming November Investor Conferences
05 nov. 2024 07h00 HE
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using...
Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update
31 oct. 2024 07h30 HE
|
Kymera Therapeutics, Inc.
KT-621 (STAT6) IND cleared by FDA and dosing in the Phase 1 clinical trial initiated, with data expected in the first half of 2025 Sanofi expanding KT-474/SAR444656 (IRAK4) Phase 2 clinical trials in...
Kymera Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader, for the Treatment of TH2 Immuno-Inflammatory Diseases
24 oct. 2024 07h00 HE
|
Kymera Therapeutics, Inc.
KT-621, an oral degrader, is the first STAT6 targeted medicine to enter clinical development, with the potential to address multiple immuno-inflammatory diseases KT-621 has demonstrated...